ClinicalTrials.gg
RecruitingNCT06991296Updated Feb 17, 2026

Concentration of n-3 PUFA Monohydroxylated Derivatives in Adults With Obesity After n-3 PUFA Supplementation.

An interventional study of SPM Active® in Obesity, sponsored by University of North Carolina, Chapel Hill. Recruiting at 1 site in United States. Open to participants aged 45 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
45 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Obesity by University of North Carolina, Chapel Hill — 5 open to participants now, 7 under way, none of them phase 3. Obesity · University of North Carolina, Chapel Hill.

Planned enrollment
56th of 67
33 · median 104
Started
2025
with 3 others
No phase
60 of 70
5 open now
Registered
66th of 70
by date

Among the 70 studies in Obesity by University of North Carolina, Chapel Hill, this one is the 56th largest by planned enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2025, is one of 60 with no phase, and was the 66th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 70 studies in Obesity by University of North Carolina, Chapel Hill are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 45 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Obesity by University of North Carolina, Chapel Hill, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if daily supplementation with SPM Active® can increase omega 3 polyunsaturated fatty acid derivatives and improve well-being in adults with obesity. The main questions it aims to answer are:

Does 2 g/day of SPM Active® for 12 weeks increase plasma levels of 14-hydroxydocosahexaenoic (HDHA), 17-HDHA, and 18-hydroxy eicosapentaenoic acid (HEPE)?

Does 2 g/day of SPM Active® for 12 weeks improve self-reported burnout, life satisfaction, and sleep quality?

Participants will:

Take two SPM Active® soft-gel capsules daily for 12 weeks (±2-4 days).

Provide 12-hour fasting blood samples before and after the intervention.

Complete validated surveys on burnout, life satisfaction, and sleep quality at baseline and study end.

Read the detailed description

Purpose: This study aims to explore the effects of 'SPM Active®,' an omega-3 polyunsaturated fatty acid (n-3 PUFA) dietary supplement, on male adults with obesity. The supplement specifically targets the increase of monohydroxylated derivatives of n-3 PUFAs, which play a crucial role in reducing chronic, low-grade inflammation. The primary objective of the study is to determine whether administering SPM Active® at 2g/day for a longer duration (3 months) leads to higher levels of the monohydroxylated derivatives (14-HDHA, 17-HDHA, and 18-HEPE) in adults with obesity (BMI between 30 and 40 kg/m\^2, n=33). The secondary objective is to evaluate whether administration of SPM Active® improves the following outcomes: a) burnout, b) life satisfaction, and c) sleep quality. These outcomes will be assessed using validated surveys administered before and after the intervention.

Participants: The study will include 33 healthy male and female participants of any ethnicity, aged 45-60 years, with a BMI of 30-40 kg/m\^2.

Procedures: The intervention involves the administration of the dietary supplement 'SPM Active®' provided by Metagenics. All participants will take 2 soft gel capsules per day for 12 weeks, with a window of +/- 2-4 days. A 12-hour fasting blood sample will be collected from each participant before and after the intervention by a licensed phlebotomist at the UNC Nutrition Research Institute (NRI) at Kannapolis, NC. Additionally, participants will complete surveys at the start and end of the study.

03

Conditions studied

  • Obesity

Keywords

  • oxylipins
  • obesity
  • fish oil
  • omega 3 fatty acids
  • inflammation
  • Body Mass Index
  • omega 3 fatty acid supplementation
04

Who can participate

Ages eligible
45 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults, ages 45-60 years
  • (BMI) between 30 and 40 kg/m\^2
  • Any race or ethnicity

Exclusion criteria

Exclusion Criteria:

  • Age \< 45 years or > 60 years
  • pregnant or breastfeeding women
  • \< 30 kg/m\^2 or > 40 kg/m\^2
  • Diagnosed type 1 or type 2 diabetes
  • Active disease, liver disease, coagulopathy, or hypothyroidism
  • Known allergy to fish or shellfish
  • Current use of any of the following medications: asthma controller therapies, anticoagulants, estrogen or testosterone, daily aspirin or NSAIDs.
  • Inability to give
  • Receiving immunomodulatory or therapy
  • Known active or undergoing treatment for malignancy
  • Use of n-3 PUFA supplements or high consumption of fatty fish (> 2 servings/week) within 3 months prior to enrollment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    SPM Active® Supplementation

    All participants will take two SPM Active® soft-gel capsules daily (total 2 g/day) for 12 weeks (± 2-4 days). Fasting blood samples will be drawn at baseline and at end-of-treatment to quantify 14-HDHA, 17-HDHA, and 18-HEPE levels. Validated surveys assessing burnout, life satisfaction, and sleep quality will be administered before and after the supplementation period.

    Dietary Supplement: SPM Active®

Interventions

  • Dietary supplementSPM Active®

    Participants will take two SPM Active® soft-gel capsules orally each day (total 2 g/day of specialized pro-resolving mediators) for 12 weeks (± 2-4 days). Capsules are provided by Metagenics and contain monohydroxylated n-3 PUFA derivatives (14-HDHA, 17-HDHA, 18-HEPE).

06

What researchers measure

Primary outcomes

  1. Change in Plasma Levels of Monohydroxylated n-3 PUFA Derivatives (14-HDHA, 17-HDHA, 18-HEPE)

    Mean change from baseline in fasting plasma concentrations of 14-HDHA, 17-HDHA, and 18-HEPE, as quantified by liquid chromatography-mass spectrometry.

    Time frame: Baseline (Day 0) and End of Treatment (Week 12 ± 2-4 days)

Secondary outcomes

  1. Change in Burnout Score

    The assessment of this survey is validated in a systematic review titled, "Maslach Burnout Inventory-General Survey: A Systematic Review and Meta-Analysis of Measurement Properties." This survey is measured on a scale form 0-6 where 0 is never experiencing the stated type of burnout and 6 being experiencing burnout every day. It is divided into three subscale measurements on emotional exhaustion, cynicism, and professional efficacy. High levels of burnout are indicated by high scores in emotional exhaustion and cynicism, along with low scores in professional efficacy.

    Time frame: Baseline (Day 0) and End of Treatment (Week 12 ± 2-4 days)

  2. Change in Life Satisfaction Score

    The life satisfaction survey assesses global life satisfaction and its validity review is conducted by William Pavot and Ed Diener in "The satisfaction With Life Scale and the merging construct of life satisfaction." This survey is measured on a scale of 1-7 where 1 is strongly disagree and 7 is strongly agree. A low score indicates low life satisfaction, whereas a high score indicates a high level of life satisfaction.

    Time frame: Baseline (Day 0) and End of Treatment (Week 12 ± 2-4 days)

  3. Change in Sleep Quality Score

    The sleep quality survey is validated by University of Pittsburgh and is detailed in "The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research." The sleep quality survey is converted to scores, where the scores range form 0-3 with a higher score being indicative of more sleep disturbances.

    Time frame: Baseline (Day 0) and End of Treatment (Week 12 ± 2-4 days)

07

Study locations

1 of 1 sites recruiting
  • UNC Nutrition Research Institute
    Kannapolis, North Carolina 28081, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: They willl be shared beginning 9 to 36 months following publication of study. Anticipated: December 2025 to March 2028.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 18 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
May 27, 2025
StartActual
Jun 2, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06991296
Collaborators
Metagenics, Inc.
Responsible party
Sponsor
First posted
May 27, 2025
Start date
Jun 2, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Saame R Shaikh, PhD
Contact
shaikhsa@email.unc.edu
317-409-9565
Rafia Virk, MS
Contact
drvirk@email.unc.edu
7036269517
Saame Shaikh, PhD
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion